Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 13, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK .
View HTML
Toggle Summary ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies
ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19 th , the cutoff date for data included in the abstract, primarily at the higher doses: 7 with CLL/SLL, 1 with FL, 1
View HTML
Toggle Summary ArQule Reports Third Quarter 2019 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 30, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019 , the Company reported a net loss of $10.7 million , or
View HTML
Toggle Summary ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Data from a phase 1 clinical trial suggest that circulating tumor DNA (ctDNA) may serve as a reliable biomarker of tumor mutational status and could be used to predict treatment response Preclinical work demonstrates treatment with ARQ 751 in combination with a variety of therapeutic agents
View HTML
Toggle Summary ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting
Treatment with miransertib prevents formation of new PIK3CA-driven vascular malformations and leads to regression of existing PIK3CA-driven vascular malformations in experimental mouse model BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 21, 2019-- ArQule , Inc.
View HTML
Toggle Summary ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019
BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Two poster presentations on ARQ 751 will highlight data from the phase 1 trial, as well as preclinical studies demonstrating the potential of ARQ 751 in combination with various therapeutic agents BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2019-- ArQule , Inc.
View HTML
Toggle Summary ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
  BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 8, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting research on the company’s pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being held from October 15 to October 19, 2019 in
View HTML
Toggle Summary ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
  MOSAIC trial represents the first registrational trial for Proteus Syndrome and PIK3CA-related overgrowth spectrum     BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 2, 2019--   ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC ( M iransertib in
View HTML
Toggle Summary ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019
  BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence , President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 2019 Cantor Global Healthcare Conference on Thursday,
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.